Skip to content
128 result(s)

GSK Medical

This online medical resource for scientific and clinical information is intended to share the latest development in clinical research on GSK Products

NMA class comparison data in COPD

UMEC/VI versus dual and mono-bronchodilator therapies

Network meta-analysis (NMA)

Comparing efficacy of dual therapies among patients with COPD

Summary

For UMEC/VI the NMA showed outcome benefits compared with other single-inhaler LAMA/LABA dual therapies and monotherapies¹

Network meta-analysis (NMA)

Comparing efficacy of triple therapies among patients with COPD

Clinical Efficacy

As well as ease of use, and having a low number of errors with an inhaler, patients need treatments that show clinical efficacy.

Inhaled molecules for COPD treatment

How does molecule pharmacology correlate with clinical efficacy and safety?

Technical Performance

Explore the technical performance of inhalers

Patient Benefits

What are the key considerations affecting inhaler choice, from a patient and physician perspective?

Test Webinar

This is a test medical event

The EMAX Trial

Explore the evidence for initial maintenance treatment with dual bronchodilators compared with bronchodilator monotherapy

NMA class comparison data in COPD

FF/UMEC/VI versus triple and dual bronchodilator therapies

Summary

For FF/UMEC/VI, the NMA suggest favourable efficacy compared with other single-inhaler triple therapies.1

GSK Medical - Please request a contact confirmation Form

Contact us form for UK healthcare professionals to contact GSK

Effectiveness and safety in patients with autoimmune diseases

Real-world evidence supporting protection from HZ in individuals with selected autoimmune diseases

Unmet Need

In this section the symptom burden and unmet needs of patients with COPD are discussed, as well as the importance of correct inhaler technique and the impact of multiple inhaler therapy.

Respiratory

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas rhoncus augue nunc, quis consectetur tortor malesuada at curabitur. Dolor sit amet, consectetur adipiscing elit. Maecenas rhoncus aug nunc, quis consectetur tortor malesuada at curabitur.

IL-5 Meetings

Espaço online onde pode aprofundar os seus conhecimentos sobre o papel pleotrópico da Interleucina 5 (IL-5).

EOS Talks Digital Classroom – EGPA

EOS Talks Digital Classroom é o seu espaço online onde pode aprofundar os seus conhecimentos sobre a incidência, controlo e tratamento das doenças eosinofílicas

EOS Talks Digital Classroom – SEA

EOS Talks Digital Classroom é o seu espaço online onde pode aprofundar os seus conhecimentos sobre a incidência, controlo e tratamento das doenças eosinofílicas

O que sabe sobre o vsr e vacina RSVPreF3?

Espaço online onde pode aprofundar os seus conhecimentos sobre o Vírus Sincicial Respiratório e vacina RSVPreF3

Disease Information

View disease information content from GSK Vaccines

Resources

View resources from medical organizations, patient advocacy organizations as well as global and local guidelines.

Vaccines

GSK Vaccines Medical

Herpes Zoster

Herpes zoster, also known as shingles, is a painful condition caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox.1-4

Varicella (chickenpox) versus herpes zoster (shingles)

Educational content on herpes zoster (shingles) for healthcare professionals

Infection, latency and reactivation

Educational content on herpes zoster (shingles) for healthcare professionals

What is herpes zoster (shingles)?

Educational content on herpes zoster (shingles) for healthcare professionals

Misunderstandings among adults

Educational content on herpes zoster (shingles) for healthcare professionals

Burden of disease and complications

Burden of disease and complications

Incidence

Educational content on herpes zoster (shingles) for healthcare professionals

Epidemiology and risk factors

Herpes zoster is caused by the reactivation of the varicella zoster virus.

Identifying patients at risk

Educational content on herpes zoster (shingles) for healthcare professionals

Signs and symptoms

Educational content on herpes zoster (shingles) for healthcare professionals

ZOE programme

The efficacy of the Recombinant Zoster Vaccine (RZV) was evaluated in two Phase 3 clinical trials, Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50, NCT01165177) and Zoster Efficacy Study in Adults 70 Years of Age or Older (ZOE-70, NCT01165229).1,2 The ZOE-LTFU (NCT02723773) is a long-term follow-up (LTFU) study of the ZOE-50 and ZOE-70 pivotal trials.3,4

Importance of cell-mediated immunity

Educational content on herpes zoster (shingles) for healthcare professionals

Complications

Educational content on herpes zoster (shingles) for healthcare professionals

Co-administration of the recombinant zoster vaccine (RZV) with other adult vaccines

Throughout life, vaccines are recommended to protect individuals from vaccine-preventable diseases.

Prevention through vaccination: Immunocompromised patients

Efficacy, immunogenicity, and safety of the adjuvanted recombinant zoster vaccine (RZV) in immunocompromised subjects

Real-world evidence for the recombinant zoster vaccine (RZV)

Since the first approval of the recombinant zoster vaccine (RZV) against herpes zoster (HZ) in 2017, evidence for its use in real-world settings has been generated through real-world studies.

Real world evidence for RZV in patients with autoimmune diseases

Real world evidence for RZV in patients with autoimmune diseases

Multidisciplinary approach to patient care

Educational content on herpes zoster (shingles) for healthcare professionals

Conservative measures

Educational content on herpes zoster (shingles) for healthcare professionals

Patient management

Treatment options for herpes zoster are suboptimal and may have limited efficacy and poor tolerability in some patients. Therefore, improvements are needed in the prevention and management of herpes zoster.1,2

Scenario 2: An unusual presentation

Educational content on herpes zoster (shingles) for healthcare professionals

Scenario 1: A high-risk patient

Educational content on herpes zoster (shingles) for healthcare professionals

Load more

Não conseguimos encontrar a informação que procura. Experimente os seguintes passos para melhorar a sua pesquisa:

  • Verifique a ortografia do termo de pesquisa
  • Experimente um termo de pesquisa diferente
  • Tente utilizar várias palavras-chave para restringir a sua pesquisa
  • Tente utilizar sinónimos ou palavras relacionadas para alargar a sua pesquisa